Control CreERT2/MLL::AF9 AML recipients that were treated with tamoxifen (blue solid line) survived longer (∼24 days), probably because of the impact of tamoxifen and/or off-target CRE activity. This evidence concerns the gene KMT2A and acute myeloid leukemia.